Palisade Bio Advances PALI-2108 to Phase 2, Reports Q2 Results and Sets Timelines for UC and Crohn's Trials
PALI has more than doubled off its 52-week low of $0.53.
Summary
Palisade Bio reported Q2 2026 financials and outlined a clear path for PALI-2108 into Phase 2. The company expects to enroll the first patient in the ASCENTRA-UC trial in 2H 2026, with primary efficacy data in 2H 2027. An IND for the Crohn's disease trial is also planned for 2H 2026, with a 1Q 2027 start and early 2028 readout. Phase 1 results showed clinical response in all five UC patients and a 47.5% reduction in SES-CD score in fibrostenotic Crohn's patients. The balance sheet is described as strong enough to fund through key readouts, though no specific cash figure was given. This follows the $300M shelf registration filed in May and the IND clearance in June, adding concrete timelines that de-risk the development program.
At the time of this announcement, PALI was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $364.5M. The 52-week trading range was $0.53 to $2.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.